Key Highlights
- SGMOQ trades around 16 cents on the OTC market, carrying the 'Q' suffix that signals Bankruptcy proceedings.
- Sangamo transitioned off Nasdaq to the OTCQB Venture Market around April 2026 before pursuing a voluntary Chapter 11 reorganization.
- The company selected successful bidders following a competitive asset auction for roughly $163.55 million in cash consideration, with agreements involving Eli Lilly and Astellas.
- In Chapter 11, common Equity typically ranks last in the distribution waterfall, meaning recovery for shareholders may be limited or nil.
Once a prominent name in genomic medicine, Sangamo Therapeutics, Inc (OTC: SGMOQ) is now a company in wind-down, and its stock reflects it. Trading around 16 cents on the over-the-counter market and carrying the 'Q' suffix that signals bankruptcy proceedings, the shares are no longer a bet on a drug pipeline but a residual claim on a court-supervised sale of assets. The recent slide lower is best understood against that backdrop rather than as a reaction to any single catalyst.
Company and Latest Development
Sangamo Therapeutics was a clinical-stage biotechnology company focused on gene therapy and genomic medicine, including zinc-finger and other genome-engineering technologies. In 2026 the company's trajectory changed decisively. After announcing an exploration of strategic alternatives, Sangamo transitioned off the Nasdaq Global Select Market to the OTCQB Venture Market around April 2026, then moved toward a voluntary Chapter 11 reorganization designed to maximize value through asset sales. It subsequently entered asset sale agreements with large pharmaceutical partners and ran a competitive auction, selecting successful bidders for consideration reported at about $163.55 million in cash.
What Is Driving Attention Around SGMOQ?
The defining driver is the Chapter 11 process and the asset auction, not the day-to-day tape. Filings and disclosures point to asset sale agreements involving Eli Lilly and Astellas, and to a court-supervised auction that concluded with selected bidders. The modest decline does not stem from a specific, independently verifiable same-day event; for a company navigating bankruptcy, the equity typically trades on shifting expectations about whether any value will remain for common shareholders after creditors are satisfied.
Key Numbers and Company Position
The verified figures center on the restructuring. Sangamo selected successful bidders following a competitive asset auction for roughly $163.55 million in cash consideration, and it had earlier struck asset sale agreements with Lilly and Astellas. The shares trade near $0.155 on the OTC market. In Chapter 11, proceeds generally flow first to secured and unsecured creditors, with common equity last in line, which is why a nominal market Capitalization figure can overstate the practical value available to shareholders.
What Could Come Next?
The path ahead runs through the bankruptcy court. Key developments to monitor include closings of the asset sales to Lilly, Astellas and other successful bidders, court approvals of the transactions, and the eventual plan of reorganization or Liquidation that determines the distribution waterfall. Any disclosures on creditor recoveries, the fate of remaining programs, and the ultimate treatment of common stock will be central.
Risks to Watch
The risks here are acute and structural. In Chapter 11, common shareholders frequently recover little or nothing once creditors are paid, and there is no assurance SGMOQ equity will retain value. The stock is illiquid, highly speculative and subject to severe Volatility on the OTC market. Deal closings can be delayed or altered, and court outcomes are uncertain.
A Court-Supervised Auction, Not a Pipeline, Now Defines Sangamo
Sangamo Therapeutics has moved from Nasdaq-listed gene-therapy hopeful to an OTC-traded company in Chapter 11, selling its Assets through a court-supervised auction that drew bids around $163.55 million and agreements with Lilly and Astellas. The decline reflects that distressed reality rather than a discrete catalyst. Investors may be watching sale closings, court approvals and any guidance on Shareholder recoveries as the developments that will define what, if anything, remains for SGMOQ holders.






Please wait processing your request...